Docetaxel Impact on Metastastic Prostate cancer patients: a quality of Life Evaluatio

• Conditions: Prostate cancer

• Registration Number: NL-OMON29025
• Lead Sponsor: none

Brief Summary

A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Pending
• Sex: Not specified
• Target Recruitment: 300

Inclusion Criteria

Age = 18 year
-Prostaatonline-participant (Patients that gave approval (in prostaatonline) for the use of data for scientific purposes)
-Treatment with docetaxel during the time of participation in prostaatonline

Exclusion Criteria

None

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary endpoint<br>Does the change of QoL differ during the time of treatment with docetaxel with respectively HSPC versus 1st line and 2nd line CRPC?<br>

Secondary Outcome Measures

Name	Time	Method
Secondary endpoint<br>•What is the change in QoL at the time of treatment with docetaxel in patients with metastatic prostate cancer?<br>•What is de absolute QoL after the last cycle from one series of treatment with docetaxel?<br>•What is de QoL six months after the last docetaxel in one series?<br>